- ICH GCP
- EU: n kliinisten tutkimusten rekisteri
Viimeisimmät kokeilut
EudraCT Number: 2022-001811-16 | Sponsor Protocol Number: PS21GAP | Start Date: | |||||||||||
Sponsor Name: Princess Maxima Center for pediatric oncology | |||||||||||||
Full Title: 68Ga-SATO in pediatric neuroblastoma patient; exploratory, safety, non-randomized, open label, comparative study | |||||||||||||
Medical condition: Neuroblastoma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002965-38 | Sponsor Protocol Number: 004 | Start Date: | ||||||
Sponsor Name: Chirurgische Gemeinschaftspraxis Südstadt | ||||||||
Full Title: Comparison of sclerotherapy for first grade haemorrhoids using Aethoxylsklerol foam versus fluid: A randomised, controlled, multicentre, single blinded trial. | ||||||||
Medical condition: Bleeding first-grade haemorrhoids | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: DE (Completed) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2008-007845-29 | Sponsor Protocol Number: P07-07 / BF 2.649 | Start Date: | |||||||||||||||||||||||||||||||
Sponsor Name: Bioprojet | |||||||||||||||||||||||||||||||||
Full Title: Prospective, randomized, double-blind study, parallel-group, multi-center trial assessing the effects of escalating doses of BF2.649 and BF2.649 add on Modafinil on cataplexy in patients with narco... | |||||||||||||||||||||||||||||||||
Medical condition: Cataplexy in patients with narcolepsy | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) HU (Completed) FR (Completed) NL (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-001033-16 | Sponsor Protocol Number: NN7008-3809 | Start Date: | |||||||||||
Sponsor Name: Novo Nordisk A/S | |||||||||||||
Full Title: Safety and Efficacy of NNC 0155-0000-0004 in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients with Haemophilia A | |||||||||||||
Medical condition: Haemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: GB (Prematurely Ended) AT (Completed) ES (Completed) GR (Completed) DK (Completed) HU (Completed) LT (Completed) PL (Completed) PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002567-62 | Sponsor Protocol Number: CK-LX3401 | Start Date: | |||||||||||
Sponsor Name: Cardiokine Biopharma, LLC | |||||||||||||
Full Title: THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation | |||||||||||||
Medical condition: Hyponatremia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) CZ (Completed) SK (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000560-22 | Sponsor Protocol Number: MT-12 | Start Date: | |||||||||||
Sponsor Name: ALK-Abelló A/S | |||||||||||||
Full Title: A one-year placebo-controlled phase III trial evaluating the efficacy and safety of the house dust mite (HDM) SLIT-tablet in children (5-11 years of age) with HDM allergic rhinitis/rhinoconjunctivi... | |||||||||||||
Medical condition: Allergic rhinitis/rhinoconjunctivitis induced by house dust mites | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) SK (Completed) DE (Completed) PL (Completed) ES (Ongoing) BG (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005493-25 | Sponsor Protocol Number: EFISS | Start Date: | |||||||||||
Sponsor Name: Fakultní nemocnice Brno | |||||||||||||
Full Title: Effect of Prophylactic Fibrinogen Concentrate In Scoliosis Surgery: A randomized pilot study (EFISS trial) | |||||||||||||
Medical condition: Scoliosis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006903-14 | Sponsor Protocol Number: ARQ-151-315 | Start Date: | |||||||||||
Sponsor Name: Arcutis Biotherapeutics, Inc. | |||||||||||||
Full Title: A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis | |||||||||||||
Medical condition: Atopic Dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002384-30 | Sponsor Protocol Number: ABR81872 | Start Date: | ||||||
Sponsor Name: Erasmus MC - Sophia | ||||||||
Full Title: Reduction of blood loss in pediatric osteotomies around the hip - A randomized placebo-controlled trial with tranexamic acid – | ||||||||
Medical condition: Osteotomies around the hip, i.e. proximal femoral and/or pelvic osteotomies (PFPO) in children, for e.g: - hip dysplasia - secondary hip dysplasia - hip incongruenties due to other problems (e.g. p... | ||||||||
|
||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||
Trial protocol: NL (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005891-41 | Sponsor Protocol Number: 109509 | Start Date: | ||||||
Sponsor Name: GlaxoSmithKline Biologicals | ||||||||
Full Title: A phase IIIb, observer-blind, controlled study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine or Prevenar whe... | ||||||||
Medical condition: Booster vaccination against Streptococcus pneumoniae or Haemophilus influenzae in healthy infants 12 to 18 months of age who were previously primed with three doses of pneumococcal conjugate vaccin... | ||||||||
|
||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||
Trial protocol: PL (Ongoing) | ||||||||
Trial results: View results |